Introduction {#S1}
============

T helper (T~H~) cells promote the development of specific types of inflammation following differentiation into various effector subsets. The cytokine microenvironment present when a naive T~H~ cell is activated determines the developmental pathway. Interleukin 4 (IL-4 \[<http://www.signaling-gateway.org/molecule/query?afcsid=A001262>\]) promotes the differentiation of T~H~2 cells and allergic inflammation. IL-12 promotes T~H~1 differentiation, while inflammatory cytokines, including transforming growth factor-β (TGF-β1), IL-6, IL-1 and IL-23, stimulate the development of T~H~17 cells, both cell types contribute to autoimmune inflammation^[@R1]--[@R3]^. T~H~ differentiation and the establishment of effector phenotypes are governed by a network of transcription factors that regulate the expression of cytokines and other effector genes. For example, T~H~2 development requires the IL-4--induced activation of STAT6, followed by the subsequent induction of GATA-3, a T~H~2 lineage-promoting factor. The ability of T~H~2 cells to respond to subsequent T cell receptor (TCR) stimulation with a rapid induction of T~H~2-specific cytokines further requires NFAT family members, Jun family members, c-maf, and IRF4, likely among other factors, to transactivate cytokine loci^[@R4]--[@R6]^.

We have described that the transcription factor PU.1 \[<http://www.signaling-gateway.org/molecule/query?afcsid=A001950>\] also contributes to the T~H~2 phenotype by promoting heterogeneity of T~H~2 cytokine secretion^[@R7],[@R8]^. PU.1 was specifically expressed in subpopulations of T~H~2 cells that had low IL-4 expression. Ectopic expression of PU.1 reduced production of most T~H~2 cytokines, while shRNA that decreased PU.1 expression, or PU.1-deficiency, increased overall cytokine production specifically in populations of cells that secreted two or more cytokines^[@R7],[@R8]^. PU.1 functions, at least in part, by limiting the ability of GATA-3 and IRF4 to interact with cytokine loci targets^[@R7]--[@R9]^.

IL-9 \[<http://www.signaling-gateway.org/molecule/query?afcsid=A001559>\] has long been thought to be a T~H~2 cytokine as it promotes allergic inflammation and is associated with various T[H]{.smallcaps}2 responses^[@R10]^. Transgenic expression of *Il9* results in allergic inflammation^[@R11]--[@R13]^. IL-9 promotes mucus production from lung epithelial cells and pulmonary mastocytosis^[@R14]--[@R17]^. While allergic inflammation can develop in *Il9*^−/−^ mice using a standard sensitization-challenge model, blockade of IL-9 in a similar model results in decreased allergic inflammation^[@R18],[@R19]^. IL-9 expression is increased in lungs of asthmatic patients^[@R20],[@R21]^, and blocking antibodies are being developed as a therapy for atopic disease^[@R22]^. IL-9 may also contribute to extracellular parasite immunity^[@R23],[@R24]^. Most recently, IL-9 has been shown to promote the development of T~H~17 cells, while increasing Treg activity^[@R25],[@R26]^, suggesting that IL-9 biology may be more complex.

In addition to established T~H~ subsets, reports have described an IL-9-secreting population of T cells^[@R27]^. T~H~2 cells and Treg cells can produce IL-9 (ref. ^[@R28]^), and culture with TGF-β1 may increase IL-9 production from multiple cell types^[@R26]^. A T~H~ subset putatively called T~H~9 cells are derived in culture with a combination of TGF-β1 and IL-4 (refs. ^[@R24],[@R29]^). These cells are related to T~H~2 cells in that they require STAT6 and GATA-3 for development, but have reduced expression of T~H~2 cytokines^[@R24],[@R29]^. Transcription factors that specifically control the IL-9--secreting T cell phenotype have not been identified.

In this report, we identified PU.1 as a regulator of IL-9 production in T cells. PU.1-deficient T cells had diminished IL-9 production and ectopic expression of PU.1 increased IL-9 production from T~H~2 or T~H~9 cultures. Diminishing PU.1 expression in human IL-9--secreting T cell cultures also decreased IL-9 production. In mice that lack PU.1 only in T cells, allergic airway inflammation was attenuated and this observation correlated with decreased IL-9 and PU.1-induced chemokine production in the lung. These results suggest that PU.1 is a critical regulator of the IL-9--secreting T cell phenotype and is important for the development of allergic inflammation.

RESULTS {#S2}
=======

PU.1 promotes the development of IL-9--secreting T cells {#S3}
--------------------------------------------------------

Initial descriptions of the IL-9--secreting T~H~ cells (hereafter called T~H~9 for simplicity) did not identify a transcription factor that distinguished these cells as a distinct lineage^[@R24],[@R29]^. We have shown that PU.1 limits T~H~2 cytokine production in T cells^[@R7],[@R8]^, suggesting that it could be involved in the T~H~9 phenotype. To test this hypothesis, we differentiated naive T cells from wild-type and PU.1-deficient (*Sfpi1*^lck−/−^) mice under T~H~9 conditions (TGF-β1 plus IL-4). We observed that IL-9 secretion, mRNA expression and IL-9 intracellular staining were decreased in T~H~9 cultures that lacked PU.1 expression ([Fig. 1a--c](#F1){ref-type="fig"}).

PU.1 expression was low in T~H~1 cells, and in T~H~2 populations was expressed in IL-4^lo^ but not IL-4^hi^ cells^[@R8]^. To compare the expression of PU.1 in additional T~H~ subsets, we generated T~H~1, T~H~2, T~H~17 and T~H~9 cells and analyzed RNA for expression of PU.1. We observed that T~H~1 and T~H~17 had the lowest expression of *Sfpi1* mRNA, T~H~2 cells had 3--5-fold more abundant expression, and T~H~9 cells expressed approximately 3-fold more *Sfpi1* than T~H~2 cells ([Fig. 1d](#F1){ref-type="fig"}). Inducible Treg cultures expressed even more *Sfpi1* mRNA than in T~H~9 cultures ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}), suggesting that *Sfpi1* might be a TGF-β-induced gene. The expression of *Sfpi1* was not STAT6-dependent as determined by comparing wild-type and *Stat6*^−/−^ T~H~9 cultures, (data not shown). As both iTreg and T~H~17 cultures have been suggested to produce IL-9 (refs. ^[@R25],[@R26],[@R28]^), we also directly compared cells cultured under these conditions to T~H~9 cultures. By intracellular staining and ELISA we observed low or undetectable amounts of IL-9 produced by iTreg cultures ([Fig. 1e](#F1){ref-type="fig"} and data not shown). In comparing T~H~9 and T~H~17 cultures, we observed little IL-9 production in T~H~17 cultures assays by intracellular staining or ELISA, though there was a low amount of IL-17 produced from T~H~9 cultures ([Fig. 1f,g](#F1){ref-type="fig"}). As IL-9 was observed in T~H~2 cultures, we separated T~H~2 populations into IL-4^hi^ and IL-4^lo^ populations^[@R8]^, and observed that *Il9* expression segregated with *Sfpi1* expression in the IL-4^lo^ cells and segregated away from *Il4* expression ([Fig. 1h](#F1){ref-type="fig"}).

To define if PU.1 was a determining factor in promoting IL-9 secretion, we ectopically expressed PU.1 using a bicistronic retrovirus in T~H~2, T~H~9 and iTreg cultures and examined cytokine secretion and gene expression in sorted EGFP^+^ cells. Increased PU.1 expression in T~H~2 or T~H~9 cultures further induced IL-9 production, assessed by both ELISA and intracellular cytokine staining, and measurement of *Il9* mRNA in these cultures ([Fig. 2a-c](#F2){ref-type="fig"}). Ectopic PU.1 expression in T~H~2 cells, as previously described, reduced the expression of T~H~2 cytokines ([Fig. 2c](#F2){ref-type="fig"}). While ectopic PU.1 expression could decrease *Foxp3* expression in iTreg cultures ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}), it did not induce *Il9* expression in these cells (data not shown). Inducible Treg generation was normal in PU.1-deficient cells, and the ability of IL-4 to repress Foxp3 was not significantly impaired in the absence of PU.1 expression ([Supplementary Fig. 1c,d](#SD1){ref-type="supplementary-material"}). Moreover, there were no significant increases in CD4^+^Foxp3^+^ cells in a variety of *Sfpi1*^lck−/−^ lymphoid organs, compared to wild-type mice ([Supplementary Fig. 1e,f](#SD1){ref-type="supplementary-material"}), suggesting that PU.1-deficiency does not affect Foxp3 expression. These results suggest that PU.1 promotes the IL-9--secreting T cell phenotype, but that additional IL-4-induced signals are required to generate T~H~9 cells.

Distinct populations secrete IL-10 and IL-9 {#S4}
-------------------------------------------

Previous reports on IL-9--secreting T cells suggested that they also express IL-10 (refs. ^[@R24],[@R29]^). In contrast, our previous report demonstrated that IL-9 and IL-10 expression in T~H~2 cells were reciprocally regulated^[@R9]^. To further examine this issue, we differentiated T~H~2 and T~H~9 cells from cultures of naïve CD4^+^ T cells using IL-4 or a combination of IL-4 and TGF-β1, respectively. While IL-10 was detected in T~H~9 cells, production was much lower than from T~H~2 cultures ([Fig. 3a,b](#F3){ref-type="fig"}). Moreover, additional treatments of T~H~9 cultures had reciprocal effects on IL-9 and IL-10 production. We observed an increase of IL-9 production from T~H~9 cultures when they were differentiated in the presence of anti-IL-10 concomitant with a decrease in IL-10 production ([Fig. 3c](#F3){ref-type="fig"}). Addition of IL-9 to T~H~2 cultures did not affect IL-10 production (data not shown). Addition of TGF-β1 to differentiated T~H~9 cultures, during anti-CD3 restimulation, increased IL-9 production, but decreased IL-10 production ([Fig. 3d](#F3){ref-type="fig"}). While PU.1-deficiency resulted in less IL-9 production ([Fig. 1](#F1){ref-type="fig"}), it did not significantly affect IL-10 production from T~H~9 cultures ([Fig. 3e](#F3){ref-type="fig"}). Thus, while T~H~9 cultures may produce IL-10, IL-9 and IL-10 are not coordinately regulated.

PU.1 is required for chromatin modifications of *Il9* {#S5}
-----------------------------------------------------

As T helper specification is associated with specific chromatin structure, we examined chromatin modifications at the *Il9* locus in naive T cells, and naive T cells cultured for five days under T~H~1, T~H~2, T~H~9 or T~H~17 conditions using chromatin immunoprecipitation (ChIP) assays. Total acetylation of both histone H3 and H4, and acetylation of H3K9 and H3K18 at two *Il9* CNS ([Fig. 4a](#F4){ref-type="fig"}) were highest in T~H~9 cultures compared to all other subsets ([Fig. 4b](#F4){ref-type="fig"}), though all subsets demonstrated an increase in acetylation compared to naïve cells. T~H~9 cells also had the lowest amount of trimethylated H3K27 (H3K27me3), a modification associated with repressed genes ([Fig. 4b](#F4){ref-type="fig"}). Cultures of iTreg cells displayed histone acetylation comparable to T~H~9 cells ([Fig. 4c](#F4){ref-type="fig"}), in agreement with data on the *Il9* locus derived from genome-wide studies^[@R30]^. However, the *Il9* locus had increased amounts of H3K27me3 in iTreg cultures compared to T~H~9 cultures ([Fig. 4c](#F4){ref-type="fig"}). Thus, active *Il9* expression was associated with a combination of high H3 acetylation and low H3K27 methylation. To test if PU.1 was required for the establishment of these chromatin modifications, we differentiated wild-type and PU.1-deficient naive T cells under T~H~9 conditions and analyzed chromatin modifications. We observed H3 acetylation, the modification that showed the greatest difference between T~H~9 and other T~H~ cultures, was decreased in the absence of PU.1 at both CNS sites ([Fig. 4d](#F4){ref-type="fig"}) and that this effect was specific for T~H~9 cultures since PU.1-deficiency did not affect H3 acetylation of *Il9* in T~H~2 or T~H~17 cells ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Moreover, the presence of the Cre transgene did not decrease *Il9* H3 acetylation ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). In contrast, H4 acetylation or H3K27 methylation were not affected by the absence of PU.1 ([Fig. 4e](#F4){ref-type="fig"}). These results suggest that PU.1 is required for programming the *Il9* locus but plays a restricted role in the histone modifications that are affected.

To determine if PU.1 was acting directly on the *Il9* gene we examined the CNS1 sequence for consensus PU.1 binding sites (5′-GGAA-3′ core sequence). We found two potential sites within sequences that were conserved among human, mouse and dog *Il9* promoters ([Fig. 4f](#F4){ref-type="fig"}). Using DNA affinity precipitation assay (DAPA) with cell extracts from T~H~2 or T~H~9 cells, followed by immunoblot, we observed PU.1 binding to both sites, with stronger binding to site 2 and binding was decreased by incubation with a non-biotinylated competitor oligonucleotide ([Fig. 4f](#F4){ref-type="fig"} and data not shown). More PU.1 binding was observed using T~H~9 extracts, parallel to increased PU.1 protein expression in T~H~9 extracts ([Fig. 4f](#F4){ref-type="fig"}). We then tested if PU.1 bound to the *Il9* promoter using ChIP assays. Following differentiation of T~H~1, T~H~2 and T~H~9 cells, PU.1 ChIP assays detected PU.1 binding to the *Il9* promoter in T~H~9 cells, with no detectable binding in T~H~1 or T~H~2 cells ([Fig. 4g](#F4){ref-type="fig"}). Thus, PU.1 binds to sites in the *Il9* promoter specifically in T~H~9 cells.

PU.1 is required for IL-9 production in human T cells {#S6}
-----------------------------------------------------

The ability of conditions that promote the development of murine T~H~9 cells to promote a human T~H~9 phenotype has not been tested. To assess the derivation of human T~H~9 cells, we cultured naive CD4^+^ T cells purified from peripheral blood under T~H~2 or T~H~9 conditions. As with murine cells, the addition of TGF-β1 to T~H~2 cultures decreased T~H~2 cytokine production and increased production of IL-9 ([Fig. 5a--c](#F5){ref-type="fig"}). Human T~H~9 cultures also expressed more *SPI1* than T~H~2 cultures ([Fig. 5a](#F5){ref-type="fig"}). We then determined if PU.1 was required for IL-9 expression in human T~H~9 cells by transfecting differentiated human T~H~9 cultures with control or *SPI1*-specific siRNA before restimulation. Inhibiting *SPI1* expression resulted in a decrease in IL-9 production ([Fig. 5d,e](#F5){ref-type="fig"}). These results suggest that the ability of PU.1 to promote the development of IL-9--secreting T cells is conserved in human and mouse cells.

T~H~9 cells and allergic inflammation {#S7}
-------------------------------------

The role of IL-9 in allergic inflammation is still unclear. To begin to explore this area further we examined IL-9 production from anti-CD3--stimulated peripheral blood mononuclear cells (PBMCs) from atopic (positive for at least one allergen-specific IgE of ten examined) and non-atopic (no allergen-specific IgE) children with ages ranging from 18-30 months. This cohort has been described in more detail elsewhere^[@R31]^. Importantly, while these children show signs of developing atopy, they have not had episodes of wheezing and are not considered to be asthmatic. IL-9 production was significantly higher from atopic patients than from non-atopic patients ([Fig. 5f](#F5){ref-type="fig"}).

To further examine a role for PU.1-dependent T cell function in allergic inflammation, wild-type and *Sfpi1*^lck−/−^ mice were subjected to a standard protocol for the development of ovalbumin (Ova)-induced allergic airway inflammation. Mice were sensitized with Ova in alum and challenged intranasally with Ova in PBS. We first tested the generation of T~H~ responses in the periphery by stimulating splenic cells with Ova or anti-CD3. Consistent with our previous *in vitro* analyses^[@R7],[@R8]^ there was no impairment of T~H~2 cytokine responses in *Sfpi1*^lck−/−^ mice, compared to wild-type mice ([Fig. 6a](#F6){ref-type="fig"}). Production of T~H~17 cytokines was also unimpaired by the absence of PU.1 ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). The generation of antigen-specific IgE and IgG1 was not significantly different between wild-type and *Sfpi1*^lck−/−^ mice (data not shown).

In contrast to the normal development of peripheral responses, inflammation in the lung was decreased in mice with PU.1-deficient T cells, compared to wild-type mice ([Fig. 6b](#F6){ref-type="fig"}). *Sfpi1*^lck−/−^ mice also demonstrated significantly decreased airway hyperresponsiveness in response to methacholine challenge than wild-type mice ([Fig. 6c](#F6){ref-type="fig"}). Analysis of bronchoalveolar lavage cellular composition demonstrated increased infiltration in wild-type and *Sfpi1*^lck−/−^ mice compared to non-challenged mice, but total cell numbers, and the cell numbers of specific cell populations, including eosinophils, were decreased in *Sfpi1*^lck−/−^ mice compared to wild-type mice ([Fig. 6d](#F6){ref-type="fig"}). To confirm that Lck-Cre-mediated deletion of the *Sfpi1* allele was not affecting PU.1-dependent development of dendritic cells important for the development of inflammation, we examined CD11b^+^ and CD103^+^ subpopulations of CD11c^+^ MHC class II^+^ cells in bronchoalveolar lavage (BAL) and lung cell suspensions of non-sensitized and non-challenged mice and observed no significant differences between wild-type and *Sfpi1*^lck−/−^ mice (data not shown). There were decreased amounts of IL-9 and T~H~2 cytokines present in BAL fluid ([Fig. 6e](#F6){ref-type="fig"}). In contrast, amounts of interferon-γ and IL-17 present in the BAL were not significantly affected (data not shown).

To demonstrate that decreases in IL-9 could result in a similar phenotype, we used the Ova-induced allergic airway inflammation model for wild-type mice treated with control or anti-IL-9 administered intravenously at the first, third and fifth challenges. We observed decreased inflammation and cell numbers of allergic inflammatory cells in mice treated with anti-IL-9, compared to control Ab-treated mice ([Fig. 6f,g](#F6){ref-type="fig"}). This result confirms a role for IL-9 in this model established using a similar protocol in BALB/c mice^[@R18]^.

To determine if *Il9* expression was lower in T cells from sensitized *Sfpi1*^lck−/−^ mice than in wild-type mice, we used qPCR to assess mRNA abundance in antigen-stimulated splenocyte cultures. We observed diminished *Il9* mRNA in *Sfpi1*^lck−/−^ cultures ([Fig. 7a](#F7){ref-type="fig"}). It was possible that PU.1 was regulating other genes associated with a T~H~9 phenotype. We have previously shown that PU.1 expression segregated with expression of *Ccl22* in IL-4^lo^ cells, and that ectopic PU.1 expression increased CCL22 production^[@R8]^. Consistent with those observations, we observed that chemokines associated with allergic inflammation, *Ccl17* and *Ccl22*, were less abundantly produced from antigen-stimulated *Sfpi1*^lck−/−^ cultures as compared to wild-type cultures ([Fig. 7a](#F7){ref-type="fig"}). Conversely, ectopic expression of PU.1 induced the expression of both chemokines in T~H~9 cultures ([Fig. 7b](#F7){ref-type="fig"}). To determine if the deficiency of chemokine production from T cells was reflected in the allergic inflammation model, we analyzed whole lung homogenates for *Ccl17* and *Ccl22* mRNA. While mRNA for both chemokines was present in tissue from sensitized and challenged mice, both were decreased in *Sfpi1*^lck−/−^ lung tissue as compared to wild-type ([Fig. 7c](#F7){ref-type="fig"}). These results suggest that PU.1 in T cells regulates allergic inflammation by inducing the expression of IL-9 and pro-allergic chemokines.

DISCUSSION {#S8}
==========

The defined phenotypes of effector T helper subsets, once classified simply as T~H~1 and T~H~2, have been expanded to include T~H~17, T~FH~ and inducible Treg cells. Most recently, an IL-9--secreting T cell, putatively termed T~H~9, was identified as arising from a cytokine combination of TGF-β1 and IL-4 (refs. ^[@R24],[@R29]^). Distinguishing these subsets has become more difficult as the plasticity between the phenotypes has become apparent^[@R32]^. However, each of the lineages express transcription factors that are lineage-determining factors or that promote particular aspects of the lineage genetic program. The T~H~9 lineage, if it is indeed a separate lineage, is related to T~H~2 by the developmental requirement for IL-4 and the downstream transcription factors STAT6 and GATA3 (refs. ^[@R24],[@R29]^). In this report, we have identified PU.1 as a transcription factor that induces the T~H~9 phenotype by promoting the expression of IL-9 and pro-allergic chemokines.

In our previous analyses of PU.1 in T~H~2 cells we noted that expression was segregated to a subpopulation of T~H~2 cells that expressed low amounts of IL-4 and other T~H~2 cytokines^[@R8]^. This observation corresponded with the ability of ectopically expressed PU.1 to inhibit the production of T~H~2 cytokines, and of decreasing PU.1 expression, either by siRNA or gene deletion, to increase T~H~2 cytokine production^[@R7],[@R8]^. This function was at least partly by interfering with factors that promote the T~H~2 phenotype including GATA3 and IRF4 (ref. ^[@R8],[@R9]^). The data presented in this report suggests that the IL-4^lo^ T~H~2 subset that we previously characterized might contain some T~H~9 cells. Given the apparent plasticity of T~H~2 cells to acquire a T~H~9 phenotype^[@R24]^, these two cell types might exist in a continuum where increasing PU.1 expression would lead to decreasing T~H~2 cytokines and increasing characteristics of the T~H~9 phenotype, with intermediate phenotypes being possible.

Our data indicate that PU.1 can bind the *Il9* promoter directly in T~H~9 cells, and that conserved PU.1 binding sites exist within CNS1. While ectopic expression of PU.1 increased characteristics of T~H~9 cells and converted T~H~2 cells to a T~H~9 phenotype, it had more modest effects on the induction of *Il9* in iTreg, T~H~1 or T~H~17 cultures (data not shown). These results might suggest that while PU.1 promotes the T~H~9 phenotype, it may be most active in cells where additional factors are present to mediate these effects. This scenario is not uncommon in the T~H~ differentiation paradigm. As described above, multiple factors contribute to the T~H~2 phenotype, and multiple factors including T-bet, STAT4, Hlx and Runx3 contribute to the T~H~1 genetic program^[@R33]--[@R35]^. One possible context requirement might be decreased expression of IRF4, which we have demonstrated represses *Il9* in T~H~2 cultures and is further required for the development of T~H~17 cells^[@R9],[@R36]^. Preliminary observations suggest that *Irf4* expression is less in T~H~9 cells than in T~H~2 cells (data not shown). The chromatin modifications present at the *Il9* locus in each of these cell types may also reflect the ability of PU.1 to induce *Il9* mRNA. The activity of the *Il9* locus correlated with the combination of increased histone acetylation and reduced H3K27 methylation. However, in iTreg cultures that had a comparable extent of histone acetylation but abundant H3K27 methylation at the *Il9* locus, *Il9* induction by PU.1 was not detected. The ability of PU.1 to induce IL-9 in T~H~2 but not iTreg cultures suggests that additional IL-4-induced factors exist that are required for acquisition of the IL-9-secreting phenotype. While GATA-3 is required for T~H~9 development^[@R29]^, it seems an unlikely candidate since it is expressed only at low amounts in T~H~9 cultures^[@R24],[@R29]^ and since we have shown PU.1 antagonizes GATA-3 activity in T~H~ cells^[@R7],[@R8]^. IRF4 also seems unlikely as it represses *Il9* expression in T~H~2 cells, and PU.1 antagonizes its function^[@R9]^. It will be interesting to determine if other transcription factors, in the presence of PU.1, promote *Il9* expression.

The relatedness between T~H~2 and T~H~9 phenotypes, and the requirement for STAT6 and GATA3 in the development of both subsets^[@R24],[@R29]^, raises some interesting questions about phenotypes that have been described in mice deficient in either STAT6 or GATA3, specifically whether phenotypes in allergic inflammation and parasite immunity are a result of defects in the development of one or both subsets. A previous report demonstrated that mice with defective TGF-β1 signaling had decreased parasite clearance that correlated with decreased IL-9 (ref. ^[@R24]^). Similarly, in this report we show defects in the development of allergic inflammation in mice that have decreased IL-9-secreting T cells, but have normal development of T~H~2 immunity. These findings suggest that T~H~9 cells might be required for what has classically been termed T~H~2 immunity and there is ample data supporting a role for IL-9 in allergic disease. Transgenic models have demonstrated that IL-9 can promote^[@R12],[@R13]^ and blockade of IL-9 inhibits^[@R18]^ the development of allergic inflammation. Moreover, increased IL-9 is found in lungs of patients with asthma^[@R20],[@R21]^, and T cells from patients with atopic disease secreted more IL-9 than non-atopic patient T cells. Importantly, this observation does not diminish the role of T~H~2 cytokines in the development of allergic inflammation, rather suggesting that these two T~H~ subsets work in concert to initiate allergic inflammation.

IL-9 can promote the development of T~H~17 cells and was reported to also be produced by T~H~17 cells^[@R25],[@R26]^. Thus the decreased allergic inflammation in mice with PU.1-deficient T cells might be interpreted to result from the decreased generation of T~H~17, which are required for the development of inflammation in this model^[@R37]^. However, we did not see decreases in the ability of PU.1-deficient T cells to acquire the T~H~17 phenotype *in vitro* and ectopic expression of PU.1 did not induce IL-17 production (data not shown). Moreover, IL-17 production from mice that are sensitized and challenged was higher in Ova-stimulated splenocyte cultures from *Sfpi1*^lck−/−^ mice than from wild-type mice. This finding suggests that PU.1 is not required for T~H~17 development. TGF-β1 appears to be an important factor in promoting IL-9 production from cells cultured with various cytokines^[@R26],[@R27]^. It is possible that while TGF-β1 promotes IL-9 production, the addition of IL-4 alters the phenotype such that T~H~17 cytokine production is decreased and resulting cells are predominantly producers of IL-9 alone. In our experiments, T~H~9 cultures produce IL-9, which was barely detectable in T~H~17 cultures, and T~H~9 cultures produced only low amounts of IL-17 compared to T~H~17 cells. Thus, while there may be overlap in the cytokine signatures of these subsets, highly polarized cells might still have distinct functional properties.

The precise contribution of PU.1-expressing T cells to allergic inflammation remains undefined, and is likely a combination of altered expression of IL-9 and chemokines. Our data confirm that blocking IL-9 with antibodies decreases allergic inflammation in the OVA-induced model. As the previous report used BALB/c mice^[@R18]^, and our study utilized C57BL/6 mice, our data demonstrate that the effects of blocking IL-9 are not strain-specific. The chemokines CCL17, CCL22 and their receptor CCR4, are each important in the development of allergic inflammation^[@R38]--[@R40]^. One possibility is that PU.1-dependent chemokine production from T cells is responsible for the diminished allergic inflammation in *Sfpi1*^lck−/−^ mice. This possibility represents an addition to the current paradigm wherein T cells in the lung secrete cytokines, such as IL-13, that promote chemokine production from resident lung cells including epithelial cells, smooth muscle cells and fibroblasts^[@R41]^. Our results suggest that T cell chemokine production also contributes to the overall extent of inflammation. PU.1-dependent IL-9 production, or the expression of other PU.1-dependent genes, may also contribute to inflammation in this model, and the phenotype we observe may indeed be caused by several different factors. As the PU.1-dependent genetic program in T cells becomes better defined, the role of these factors can be assessed more directly.

The recent description of an IL-9-secreting T cell population added further complexity to effector T~H~ phenotypes. One factor that prevented this population from initially being termed a lineage was the absence of an identified transcription factor that conferred lineage-specific expression. Our work has identified PU.1 as a factor that promotes the T~H~9 phenotype by both repressing T~H~2 cytokine production and increasing IL-9 production. PU.1 is likely not the only factor that promotes this lineage, but will be an important component of continuing investigations into T~H~ heterogeneity.

METHODS {#S9}
=======

Methods and any associated references are available in the online version of the paper.
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![PU.1 is required for optimal IL-9 production in murine T cells. Wild-type and *Sfpi1*^lck−/−^ naïve CD4^+^ T cells were cultured under T~H~9 conditions. (**a**) After five days of culture, cells were stimulated with anti-CD3 and supernatants after 1, 2 or 3 days of stimulation were tested for IL-9 using ELISA. (**b**) RNA was isolated from wild-type and *Sfpi1*^lck−/−^ T~H~2 and T~H~9 cultures after stimulation with anti-CD3. *Il9* mRNA was assessed using qPCR. (**c**) Wild-type and *Sfpi1*^lck−/--^ T~H~9 cultures were stimulated with PMA-ionomycin for 5 h before intracellular staining for IL-9. Results in (**a-c**) are the average of 3 mice and representative of more than four experiments. (**d)** Naïve CD4^+^ T cells cultured under T~H~1, T~H~2, T~H~9 or T~H~17 conditions were analyzed for *Sfpi1* expression using qPCR. Results are an average of 3-5 experiments. (**e**) Naïve CD4^+^ T cells were cultured under T~H~9 or iTreg conditions for five days and stimulated with anti-CD3 for 6 h before intracellular staining for IL-9 and Foxp3. (**f,g**) Naïve CD4^+^ T cells were cultured under T~H~9 or T~H~17 conditions for five days and stimulated with (f) PMA-ionomycin for 6 h before intracellular staining for IL-9 and IL-17 or (**g**) anti-CD3 for 24 h before supernatants were collected for analysis using ELISA. Results in (**e-g**) are representative of at least three experiments. (**h**) T~H~2 cultures were separated into IL-4^lo^ and IL-4^hi^ populations using magnetic selection. RNA was isolated from separated cells to examine expression of *Il4*, *Il9* and *Sfpi1*. Results are an average of three experiments. \*, *P* \< 0.05 using two-tailed student *t* test.](nihms-190935-f0001){#F1}

![PU.1 promotes IL-9 production. T~H~9 (**a,c**) or T~H~2 (**b,c**) cultures were transduced with control (MIEG) or PU.1-expressing retroviruses. (**a,b**) EGFP-positive cells were sorted and stimulated to determine secretion of IL-9 (top) and *Il9* expression (bottom). (**c**) IL-4 and IL-9 production was determined by intracellular staining in the EGFP+ populations of control and PU.1-transduced cells. Percentages in each quadrant are the average of results from 2-3 mice. Data are representative of 2-3 experiments.](nihms-190935-f0002){#F2}

![IL-9 and IL-10 are not coordinately regulated in T~H~9 cells. (**a**) Naïve CD4^+^ T cells were cultured under T~H~2 or T~H~9 conditions for five days before cells were left unstimulated or stimulated with plate-bound anti-CD3 for 6 or 24 hours and RNA was isolated for qPCR analysis of *Il9* and *Il10*. (**b**) T~H~2 and T~H~9 cultures derived as in **a** were stimulated for 5 hours before intracellular cytokine analysis of IL-10 and IL-9. (**c**) Naïve CD4^+^ T cells were cultured under T~H~9 conditions in the presence or absence of anti-IL-10. After five days in culture cells were restimulated with anti-CD3 and supernatants were analyzed for cytokines using ELISA. (**d**) Naïve CD4^+^ T cells were cultured under T~H~9 conditions. After five days in culture, cells were restimulated with anti-CD3 in the presence or absence of TGF-β1 and supernatants were analyzed for cytokines using ELISA. (**e**) Wild-type and *Sfpi1*^lck−/−^ naïve CD4^+^ T cells were cultured under T~H~9 conditions for five days, and stimulated with anti-CD3 for 24 hours before supernatants were tested for IL-10 using ELISA. Results are representative of at least three experiments.](nihms-190935-f0003){#F3}

![Histone modifications at the *Il9* locus. (**a**) VISTA plot of conserved non-coding sequences adjacent to the *Il9* locus. (**b,c**) Naïve CD4^+^ T cells were isolated and analyzed directly or differentiated under T~H~1, T~H~2, T~H~9, T~H~17 or iTreg culture conditions for five days. Cells were analyzed for histone modifications using chromatin immunoprecipitation for the indicated histone modifications and primers for *Il9* CNS. (**d,e**) Wild-type and *Sfpi1*^lck−/−^ naïve CD4^+^ T cells were cultured under T~H~9 conditions and used for ChIP analysis as described in **b** performed for AcH3 at CNS1 and CNS2 (**d**), or for AcH4 and me3H3K27 at CNS1 (**e**). (**f**) Top, consensus PU.1 binding sites in the *Il9* CNS1. Bottom, DAPA analysis of PU.1 binding from T~H~2 or T~H~9 extracts to site 2. For competition, extracts were incubated with a 5-fold excess of unlabelled PU.1 consensus double-stranded oligonucleotide. Expression of PU.1 in each cell extract is shown as input. Results are representative of three experiments. (**g**) Naïve CD4^+^ T cells were differentiated under T~H~1, T~H~2, or T~H~9 culture conditions for five days. Cells were analyzed for PU.1 binding by ChIP with primers for *Il9*CNS1. Results of ChIP experiments are shown as average ± SD of percent input with control IgG subtracted (a-e) or with anti-PU.1 and IgG control ChIP values shown separately (g) and are representative of 2-4 experiments.](nihms-190935-f0004){#F4}

![PU.1 promotes IL-9 production in human T cells. (**a**) Naïve human CD4^+^ T cells were cultured under T~H~2 or T~H~9 conditions and after five days in culture restimulated to analyze gene expression by qPCR. (**b,c**) T~H~2 and T~H~9 cultures were derived as in **a** and **b** supernatants from cells stimulated for 24 hours were tested for IL-9 production using ELISA or (c) cells were stimulated with anti-CD3 for 6 hours for analysis of IL-9 and IL-13 by intracellular cytokine staining. (**d,e**) Th9 cultures derived as in **a** were transfected with control or *SPI1*-specific siRNA. Twenty-four hours after transfection cells were analyzed for *SPI1* expression by qPCR (**d**) and IL-9 production using ELISA (**e**). Results in (a-e) are representative data from 3-5 experiments with different donors. (**f**) PBMCs from infants (age 18-30 months) classified as atopic (n= 49) or non-atopic (n= 33) based on positive allergen-specific serum IgE, were stimulated with anti-CD3 for 48 hours and supernatants were tested for production of IL-9 using multiplex analysis. \*, p\<0.04 using an unpaired student t test.](nihms-190935-f0005){#F5}

![PU.1 expression in T cells is required for the development of allergic inflammation. Wild-type and *Sfpi1*^lck−/−^ mice were sensitized and challenged intranasally with ovalbumin. Forty-eight hours after the last intranasal challenge mice were sacrificed for analysis. (**a**) Splenocytes were stimulated with anti-CD3 (left) or Ova (right) for 72 h and supernatants were tested for the amounts of T~H~2 cytokines by ELISA. (**b**) Lungs of challenged (C) or non-challenged (NC) mice were embedded in paraffin and analyzed by H/E staining. Magnification is indicated in the panel. (**c**) Wild-type and *Sfpi1*^lck−/−^ mice were analyzed for airway hyperreactivity using whole body plethysmography 24 h after the last intranasal challenge. Airway function was tested at baseline (B), with saline inhalation (S) and following inhalation of the indicated doses of methacholine. (**d**) Numbers of cells recovered by bronchoalveolar lavage in challenged or non-challenged mice (left). Numbers of specific cell types in BAL from challenged mice, as determined by flow cytometry, are indicated (right). (**e**) Amounts of IL-9 and T~H~2 cytokines present in BAL fluid were determined using ELISA. (**f, g**) Wild type mice were sensitized and challenged intranasally with ovalbumin daily for five days. Mice were injected intravenously with control Ig or anti-IL-9, 30 minutes before the first, third and fifth intranasal challenge. Forty-eight hours after the last intranasal challenge, lungs were processed for histological analysis (**f**) as in **b**, and BAL cells were harvested and analyzed (**g**) as in **d**. \*, p\<0.05 using two-tailed student t test. All results are the average ± SEM of 5-7 mice and are representative of three experiments.](nihms-190935-f0006){#F6}

![PU.1 is required for IL-9 and chemokine expression in allergen sensitized mice. (**a**) RNA isolated from Ova-stimulated splenocytes as described in ([Fig. 6a](#F6){ref-type="fig"}) was analyzed for expression of *Il9* and chemokines associated with allergic inflammation. (**b**) T~H~9 cultures were transduced with control (MIEG) or PU.1 expressing retroviruses. EGFP-positive cells were sorted and stimulated to determine expression of *Ccl17* and *Ccl22*. (**c**) Total lung RNA was isolated from sensitized and challenged WT and *Sfpi1*^lck−/−^ mice, or WT non-challenged (NC) mice, and analyzed for *Ccl17* and *Ccl22* mRNA by qPCR. \*, p\<0.05 using two-tailed student t test.](nihms-190935-f0007){#F7}
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